G17DT Immunogen
Identification
- Generic Name
- G17DT Immunogen
- DrugBank Accession Number
- DB04914
- Background
G17DT Immunogen is a vaccine that neutralizes gastrin-17, a hormone required for the growth of a number of cancers of the gastrointestinal tract. It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine. It is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan.
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Vaccines
Other vaccines - Synonyms
- Anti-gastrin 17 immunogen
- Antigastrin 17
- G17DT
- G17DT (AN ANTIGASTRIN IMMUNOGEN)
- G17DT Immunogen
- GASTRIMMUNE
- Gastrin 17 immunogen
- Gastrin 17 vaccine
- Gastrin 17C Diphtheria Toxoid Immunogen
Pharmacology
- Indication
Intended for the treatment of various forms of cancer.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
G17DT is a vaccine which neutralizes the gastrin 17 (G17) hormone and glycine-extended gastrin 17. G17 is a growth factor for pancreatic, stomach and colorectal cancers, and a potent stimulator of gastric acid secretion. G17DT consists of a protein carrier (Diptheria Toxoid) and a synthetic peptide which is similar to a portion of the gastrin 17 hormone. These are contained in a 'slow-release' liquid suspension vehicle for intramuscular administration. G17DT is administered by injection, the initial schedule for injection is unclear at present but booster doses are given at approximately six monthly intervals.
- Mechanism of action
When administered, G17DT induces an immune response producing antibodies which bind with the peptide and also cross-react and neutralise gastrin 17 thus inhibiting the growth of gastrointestinal cancers and metastasis. In addition the product neutralizes glycine-extended gastrin 17 which is also a stomach and pancreatic cancer growth factor.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of G17DT can be decreased when used in combination with Abatacept. Adalimumab The therapeutic efficacy of G17DT can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of G17DT can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of G17DT can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of G17DT can be decreased when used in combination with Alemtuzumab. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Gastrimmune / Insegia
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
References
- General References
- Authors unspecified: Gastrin 17 vaccine--Aphton: Anti-gastrin 17 immunogen, G17DT. BioDrugs. 2003;17(3):223-5. [Article]
- Gilliam AD, Watson SA: G17DT: an antigastrin immunogen for the treatment of gastrointestinal malignancy. Expert Opin Biol Ther. 2007 Mar;7(3):397-404. [Article]
- Ajani JA, Hecht JR, Ho L, Baker J, Oortgiesen M, Eduljee A, Michaeli D: An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 2006 May 1;106(9):1908-16. [Article]
- He AR, Marshall JL: Clinical experiences with G17DT in gastrointestinal malignancies. Expert Rev Anticancer Ther. 2006 Apr;6(4):487-92. [Article]
- Watson SA, Gilliam AD: G17DT--a new weapon in the therapeutic armoury for gastrointestinal malignancy. Expert Opin Biol Ther. 2001 Mar;1(2):309-17. [Article]
- Brett BT, Smith SC, Bouvier CV, Michaeli D, Hochhauser D, Davidson BR, Kurzawinski TR, Watkinson AF, Van Someren N, Pounder RE, Caplin ME: Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 2002 Oct 15;20(20):4225-31. [Article]
- Gilliam AD, Watson SA, Henwood M, McKenzie AJ, Humphreys JE, Elder J, Iftikhar SY, Welch N, Fielding J, Broome P, Michaeli D: A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol. 2004 Jun;30(5):536-43. [Article]
- Takhar AS, Gilliam AD, Watson SA, Henwood M, Rowlands BJ, Broome P, Beckingham IJ: The effect of jaundice on the generation of anti-gastrin antibodies in G17DT immunized patients with advanced pancreatic cancer. Eur J Surg Oncol. 2006 Mar;32(2):197-200. Epub 2005 Oct 24. [Article]
- External Links
- PubChem Substance
- 347909846
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Esophageal Cancer / Gastric Cancer 1 3 Completed Treatment Pancreatic Cancer 3 2 Completed Treatment Colorectal Cancer 4 2 Completed Treatment Gastric Cancer 4 2 Completed Treatment Jaundice / Pancreatic Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at October 21, 2007 22:23 / Updated at July 18, 2023 22:56